Showing 9831-9840 of 20874 results for "".
Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance
https://reachmd.com/programs/Audioabstracts/infliximab-trough-levels-induction-predict-treatment-failure-during-maintenance/9940/A detailed review of a study regarding the impact of the pharmacokinetics of IFX at induction on treatment failure.IUD Reduces Blood Loss by 90% in Patients with Heavy Menstrual Bleeding
https://reachmd.com/programs/advances-in-womens-health/iud-reduces-blood-loss-by-90-in-patients-with-heavy-menstrual-bleeding/15366/The use of levonorgestrel 52-mg IUD greatly reduced blood loss in patients with heavy menstrual bleeding, according to research presented at ACOG.Journal of Cystic Fibrosis: Efficacy and Safety of Levofloxacin Inhalation Solution (APT-1026) in Stable Cystic Fibrosis Patients
https://reachmd.com/programs/Audioabstracts/journal-cystic-fibrosis-efficacy-safety-levofloxacin-inhalation-solution-apt-1026/8217/A study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients.Understanding the Role of the Complement Pathways in IgAN
https://reachmd.com/programs/clinicians-roundtable/understanding-the-role-of-the-complement-pathways-in-igan/14911/Explore the two pathways that are key to the pathophysiology of IgA nephropathy and how they can impact the treatment of this rare disease.Fecal Transplants: The Future of IBD Therapy?
https://reachmd.com/programs/crohns-colitis-foundation-perspectives/fecal-transplants-the-future-ibd-therapy/9609/Fecal transplants: the "inside poop" on an emerging IBD therapyImpact of Specialized Inpatient IBD Care on Outcomes of IBD Hospitalizations
https://reachmd.com/programs/Audioabstracts/impact-specialized-inpatient-ibd-care-outcomes-ibd-hospitalizations/8408/A look into the implementation of specialized inpatient IBD care for modifying short-term and long-term clinical outcomes for hospitalized patients.Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
https://reachmd.com/programs/cme/navigating-treatment-selection-after-first-line-cdk46-inhibitor-progression/67123/Explore clinical strategies for oral SERDs and PROTACs in ER+/HER2− metastatic breast cancer, including sequencing, safety, and treatment selection.IL-31’s Role in Atopic Dermatitis and Prurigo Nodularis: Neuroimmune Insights
https://reachmd.com/programs/dermconsult/il-31-neuroimmune-insights-dermatitis-prurigo/51037/What if IL-31 is more than just the “itch cytokine”? Joining Dr. Raj Chovatiya to help answer that question and explore IL-31’s expanding role in inflammatory skin disease is Dr. Nicholas Mollanazar. Together, they examine how IL-31 bridges immune signaling, sensory nerve activation, and skin barrieCOVID-19 Vaccine Strategy: Understanding Broader Impacts
https://reachmd.com/programs/clinicians-roundtable/covid-vaccine-strategy-broad-impacts/48854/Effective vaccine guidance requires more than evaluating individual-level outcomes—it demands a comprehensive understanding of population dynamics, economic burden, and societal impact. Learn more with Dr. Darilyn Moyer, Executive Vice President and Chief Executive Officer of the American College ofAn Analysis of Subcutaneous Versus Intravenous Atezolizumab in NSCLC
https://reachmd.com/programs/spotlight-subcutaneous--cancer-immunotherapy/an-analysis-of-subcutaneous-versus-intravenous-atezolizumab-in-nsclc/32992/How does subcutaneous atezolizumab compare to intravenous? Here’s what a clinical trial determined after evaluating the two approaches side by side.